NCT02108301

Hepatitis C in Renal Transplant Recipients

Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Prof. Dr. Alice Schmidt · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The aim of the present trial is to evaluate whether the conversion of immunosuppression from tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal transplant recipients.

Conditions

• Chronic Hepatitis C-virus Infection
• Renal Transplantation

Interventions

Type	Name	Description
DRUG	tacrolimus-cyclosporine A	conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-06-01
• First posted: 2014-04-09
• Last updated: 2014-04-11

Locations

1 site across 1 country: Austria